Clinical trials: Lung Cancer Metastatic
Breast Cancer, Non-small Cell Lung Carcinoma
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
- Trial name
- NCT04042701
- Testing
- Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 115 people
- Sponsor
- Daiichi Sankyo
Non-Small Cell Lung Cancer
Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy
This study intends to describe the real-life effectiveness and safety of nivolumab in advanced NSCLC patients in Germany, as well as the patient profile, pattern of use and the quality of life.
- Trial name
- ENLARGE-Lung (NCT02910999)
- Where
- Germany
- Volunteers
- 868 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.
- Trial name
- NCT04951648
- Testing
- Almonertinib, chemotherapy
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose [RP2CD]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents…
- Trial name
- KaRAnaSa (NCT07227025)
- Testing
- Amivantamab, Olomorasib
- Where
- 12 sites in United States, Canada and 3 more
- Volunteers
- 60 people
- Sponsor
- Janssen Research & Development, LLC
Non-Small-Cell Lung Cancer
A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without famitinib in patients with advanced or metastatic NSCLC
- Trial name
- NCT04699968
- Testing
- SHR-1701，Famitinib, SHR-1701
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
- Trial name
- NCT06105021
- Testing
- AFNT-211
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Affini-T Therapeutics, Inc.
NSCLC
Iressa as Second Line Therapy in Advanced NSCLC-Asia
This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The total number of patients expected to be exposed to study procedures is approximately 150 patients will be recruited by investigational…
- Trial name
- ISTANA (NCT00478049)
- Testing
- Gefitinib, Docetaxel
- Where
- 4 sites in South Korea
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
- Trial name
- KRYSTAL-12 (NCT04685135)
- Testing
- MRTX849, Docetaxel
- Where
- 380 sites in United States, Australia and 22 more
- Volunteers
- 453 people
- Sponsor
- Mirati Therapeutics Inc.
Carcinoma, Non-Small-Cell Lung, Melanoma
Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)
This study has been designed to evaluate the safety of pembrolizumab in participants in India with unresectable or metastatic melanoma and participants with non-small cell lung cancer (NSCLC) who are either untreated (programmed…
- Trial name
- NCT03715205
- Testing
- Pembrolizumab
- Where
- 8 sites in India
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced or Metastatic Solid Tumors, Squamous-cell Non-small Cell Lung Cancer
HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors
This Phase1, multicenter, first-in-human, open-label, dose-escalation, and dose expansion study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX35 administered as a single-agent…
- Trial name
- NCT05360381
- Testing
- HLX35
- Where
- 2 sites in China
- Volunteers
- 82 people
- Sponsor
- Shanghai Henlius Biotech
NSCLC Brain Metastasis
Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.
This is a randomized, controlled, open-label, phase III trials. The main purpose of this study is to evaluate the effectiveness and safety of tumor treating felds (TTF) combined with stereotactic radiosurgery (SRS) in the…
- Trial name
- NCT06716775
- Testing
- Tumor treating felds (TTF), Best Standard of Care
- Volunteers
- 200 people
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Non-small-Cell Lung Cancer
A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)
This prospective, observational study is to assess the long-term effectiveness and safety of Atezolizumab in patients with advanced non-small cell lung cancer in clinical practice.
- Trial name
- NCT03645330
- Where
- 198 sites in Japan
- Volunteers
- 1,026 people
- Sponsor
- Chugai Pharmaceutical
Patients With Non-Small Cell Lung Cancer
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance.
- Trial name
- ARTEMIA (NCT06472245)
- Testing
- OSE2101, Docetaxel, NGS HLAA2 assay
- Where
- 207 sites in United States, Belgium and 12 more
- Volunteers
- 363 people
- Sponsor
- OSE Immunotherapeutics
Non-small Cell Lung Cancer, Lung Cancer
ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
This large phase III clinical study is studying the effect of vandetanib (ZACTIMA) in treating non-small cell lung cancer (NSCLC).
- Trial name
- ZODIAC (NCT00312377)
- Testing
- Docetaxel, Vandetanib
- Where
- 156 sites in United States, Argentina and 23 more
- Volunteers
- 1,690 people
- Sponsor
- Genzyme, a Sanofi Company
Brain Metastases, Lung Cancer Metastatic
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
The study will use an Ommaya reservoir that drains into brain metastases to deliver activated, autolous dendritic cells to the tumor lesion, for patients who are 18 - 75 years old who have brain metastases from either lung cancer…
- Conditions
- Brain Metastases, Lung Cancer Metastatic, Breast Cancer Metastatic
- Trial name
- NCT03638765
- Testing
- DCVax-Direct
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northwest Biotherapeutics
Carcinoma, Non-Small-Cell Lung
Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
Phase I study. To determine the MTD (Maximum Tolerated Dose) of nintedanib + weekly Docetaxel in patients with locally advanced or metastatic lung adenocarcinoma after failure of platinum-based first line chemotherapy.
- Trial name
- NCT02668393
- Testing
- Docetaxel, Nintedanib
- Where
- 4 sites in France, Germany
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
The objectives of this study are to assess the safety, tolerability, pharmacokinetics and efficacy of VAL401 in the treatment of patients with locally advanced or metastatic non-small cell lung adenocarcinoma.
- Trial name
- NCT02875340
- Testing
- VAL401
- Volunteers
- 8 people
- Sponsor
- ValiSeek Limited
Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
This study is carried out to see how Caucasian patients with lung cancer which has EGFR mutation will respond to gefitinib (IRESSA™) as a first line treatment.
- Trial name
- IFUM (NCT01203917)
- Testing
- Gefitinib
- Where
- 61 sites in Bulgaria, France and 11 more
- Volunteers
- 1,060 people
- Sponsor
- AstraZeneca
SCLC
Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection
The purpose of this study is to evaluate the safety and efficacy of Zepzelca™ inj. in real-world practice and to investigate important identified risks and gaps in information related to risk management plans.
- Trial name
- NCT06021483
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
This prospective, multicenter, non-interventional study (NIS) in Germany aims to collect real-life data of patients with non-squamous (NSQ) metastatic non-small cell lung cancer (mNSCLC) (incl.
- Trial name
- NAUTIC (NCT06494540)
- Where
- 30 sites in Germany
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.